Enveric Biosciences, Inc. (ENVB) |
|
3.94 -0.13 (-3.19%)
|
06-09 13:34 |
|
Open: |
4.06 |
Pre. Close: |
4.07 |
|
High:
|
4.105 |
Low:
|
3.91 |
|
Volume:
|
35,648 |
Market Cap:
|
8(M) |
|
|
|
Technical analysis |
as of: 2023-06-09 1:44:36 PM |
|
Short-term rate:
|
  |
| Stoxline posted a SELL today, upgraded from strong sell. Downward movement continues, but could change at any time. |
|
Mid-term rate:
|
  |
| Target: |
Six months: 5.65 One year: 8.15 |
| Support: |
Support1: 1.38 Support2: 1.15 |
| Resistance: |
Resistance1: 4.84 Resistance2: 6.98 |
| Pivot: |
3.98 |
| Moving Average: |
MA(5): 4.16 MA(20): 3.46
MA(100): 2.34 MA(250): 4.13 |
| MACD: |
MACD(12,26): 0.5 Signal(9): 0.5 |
| Stochastic oscillator: |
%K(14,3): 39.7 %D(3): 46.8 |
| RSI: |
RSI(14): 56.5 |
| 52-week: |
High: 18.5 Low: 1.29 |
| Average Vol(K): |
3-Month: 3,722 (K) 10-Days: 346 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ENVB ] has closed above bottom band by 47.7%. Bollinger Bands are 80.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 15 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
4.15 - 4.18 |
4.18 - 4.2 |
|
Low:
|
3.85 - 3.87 |
3.87 - 3.9 |
|
Close:
|
4.03 - 4.07 |
4.07 - 4.11 |
|
Company Description |
|
Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida. |
Headline News |
Wed, 07 Jun 2023
How Will the Market React to Enveric Biosciences Inc (ENVB) Stock Getting a Bullish Rating - InvestorsObserver
Wed, 07 Jun 2023
Enveric Biosciences Announces Two Poster Presentations at the ... - Business Wire
Mon, 05 Jun 2023
Enveric Biosciences Granted Notice of Allowance for EVM301 ... - Best Stocks
Tue, 30 May 2023
Healthcare Stocks on the Move Tuesday: AVAH, MNPR, TARO, ABSI, TCRX, BHG, ENVB, AVIR - InvestorsObserver
Thu, 25 May 2023
Enveric Biosciences Inc (ENVB) has fallen 16.22% Thursday In Premarket Trading - InvestorsObserver
Wed, 24 May 2023
Healthcare Stocks Moving Up and Down Wednesday: ENVB, ZURA, KMDA, RETA, BHG, CWBR, PTCT, ELEV - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
2 (M) |
| Shares Float |
2 (M) |
|
% Held by Insiders
|
12.5 (%) |
|
% Held by Institutions
|
8.4 (%) |
|
Shares Short
|
23 (K) |
|
Shares Short P.Month
|
22 (K) |
Stock Financials |
|
EPS
|
-10.68 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
5.01 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-52.2 |
|
Return on Equity (ttm)
|
-103.9 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-9.47 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-18 (M) |
|
Levered Free Cash Flow
|
-10 (M) |
Stock Valuations |
|
PE Ratio
|
-0.37 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.78 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-0.47 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
